Session » Osteoporosis & Metabolic Bone Disease – Basic & Clinical Science Poster

Date: Monday, November 18, 2024

Time: 10:30AM-12:30PM

Meeting: ACR Convergence 2024

10:30AM-12:30PM: Abstract Number: 2132

A Quality Improvement Initiative to Increase Osteoporosis Screening in Internal Medicine Resident Led Primary Care Clinics

10:30AM-12:30PM: Abstract Number: 2143

Analysis of Effectiveness and Safety of Romosozumab in Patients with Very High Risk of Fracture in a Spanish Population

10:30AM-12:30PM: Abstract Number: 2126

Analysis of the Evolution of Bone Mineral Density in the Spanish Population: Results of the OsteoSER Study

10:30AM-12:30PM: Abstract Number: 2116

Artificial Intelligence Classifier for Osteoporosis Detection from Chest Radiographs: Performance Evaluation and Literature Comparison with Quantitative Ultrasound

10:30AM-12:30PM: Abstract Number: 2115

Clinical Impact of Acute Symptomatic Vertebral Fractures in the United States: An Observational Study

10:30AM-12:30PM: Abstract Number: 2142

Comparison of Bone Mineral Density at the Distal Radius, Hip, and Lumbar Spine in Female Patients Undergoing Surgery for Proximal Femur or Distal Radius Fractures: Implications for Osteoporosis Diagnosis

10:30AM-12:30PM: Abstract Number: 2114

CT and DXA Bone Fragility Evaluation After Bariatric Surgery

10:30AM-12:30PM: Abstract Number: 2118

Cytotoxic T Lymphocyte Antigen-4 Improves Osteoporosis in Patient with Rheumatoid Arthritis

10:30AM-12:30PM: Abstract Number: 2135

Disability, Functional Limitation, and Use of Anti-fracture Drug Therapies in a Cohort of 3651 U.S. Adults with Osteogenesis Imperfecta

10:30AM-12:30PM: Abstract Number: 2112

Discontinuation and Non-Publication of Osteoporosis Studies: An Observational Analysis of 7,670,624 Patients

10:30AM-12:30PM: Abstract Number: 2113

Discontinuation and Non-publication of Postmenopausal Osteoporosis Clinical Studies: A Cross-sectional Analysis of 345,435 Patients

10:30AM-12:30PM: Abstract Number: 2136

Distal Radius Correlation with Femur and Lumbar Spine T-scores: A Comprehensive Analysis

10:30AM-12:30PM: Abstract Number: 2138

DXA-derived 3D Parameters of the Hip Discriminate Prevalent Fragility Fractures in Individuals with Axial Spondyloarthritis

10:30AM-12:30PM: Abstract Number: 2123

Epidemiology of Bone Health and Fracture in Gout Patients

10:30AM-12:30PM: Abstract Number: 2120

EvaluationofBone Mineral Densityand Trabecular Bone Score in JuvenileSystemicLupusErythematosusPatientsUsing Dual-Energy X-rayAbsorptiometry

10:30AM-12:30PM: Abstract Number: 2129

Fracture Risk Assessment Tool (FRAX®) Scores Predict Mortality in Community-Dwelling Elderlies

10:30AM-12:30PM: Abstract Number: 2137

Fractures Post Lung Transplant: A Retrospective Cohort Study Conducted at an International Transplant Center

10:30AM-12:30PM: Abstract Number: 2140

Frailty Is Associated with Lower Bone Mineral Density in US Veterans with Rheumatoid Arthritis

10:30AM-12:30PM: Abstract Number: 2139

Generation of a Human 3D Bone Model to Mimic Glucocorticoid- induced Osteoporosis In Vitro

10:30AM-12:30PM: Abstract Number: 2141

Glucocorticoid Therapy-Associated Bone Fractures Are Associated with Osteoporosis Underscreening in Patients with Rheumatoid Arthritis

10:30AM-12:30PM: Abstract Number: 2119

IL-17 Blockade Therapy Improves Symptoms in Patients with Active Axial Spondyloarthritis Without Occurrence of New Vertebral Fractures

10:30AM-12:30PM: Abstract Number: 2148

Impact of Hip Fractures in the Elderly Population: Functional Status, Readmission, and One-Year Mortality

10:30AM-12:30PM: Abstract Number: 2144

Impact of Immunogenicity on Clinical Outcomes in Postmenopausal Women with Osteoporosis: Results from a Randomized Controlled Phase 3 Study to Compare CT-P41 (Proposed Denosumab Biosimilar) and Reference Denosumab

10:30AM-12:30PM: Abstract Number: 2121

Increased Fracture Rates in Patients Continuing Methotrexate After Methotrexate-associated Lower Limb Insufficiency Fractures: A Retrospective Follow-up Study

10:30AM-12:30PM: Abstract Number: 2134

PEX5 Acts as a Negative Regulator of RANKL-induced Osteoclastogenesis In Vitro and Inflammatory Calvarial Bone Destruction In Vivo

10:30AM-12:30PM: Abstract Number: 2130

Post-fracture Survival for Rheumatoid Arthritis Patients Is Not Improving

10:30AM-12:30PM: Abstract Number: 2147

Primary and Secondary Prevention of Osteoporotic Fracture in the Elderly Patients

10:30AM-12:30PM: Abstract Number: 2127

Relationship Between Serum Uric Acid and Trabecular Bone Score (TBS) in Healthy Population

10:30AM-12:30PM: Abstract Number: 2122

Rheum for Improvement: Screening and Treatment of Glucocorticoid Induced Osteoporosis

10:30AM-12:30PM: Abstract Number: 2131

Role of LECT2 in the Regulation of Bone Metabolism In Vitro and In Vivo

10:30AM-12:30PM: Abstract Number: 2125

Strengthening Fracture Risk Prediction in Rheumatoid Arthritis: Integrating a Self-report Sarcopenia Screening Tool (SARC-F) and Fracture Risk Assessment Tool (FRAX) Scores

10:30AM-12:30PM: Abstract Number: 2145

Study of Bone Metabolism in Patients Diagnosed with Osteogenesis Imperfecta.

10:30AM-12:30PM: Abstract Number: 2117

The Risk of Medication-related Osteonecrosis of the Jaw (MRONJ) in a Patient with Osteoporosis Treated with Antiresorptive Therapy and Undergoing Dental Care Is Negligible with a CTX Threshold Above 260

10:30AM-12:30PM: Abstract Number: 2128

Trabecular Bone Score Curve from a Qatari Population, Data from Qatar Biobank

10:30AM-12:30PM: Abstract Number: 2133

Unveiling the Association Between Low-Density Lipoprotein Cholesterol Lowering and Fracture Risk Among Patients with Hyperlipidaemia in a Population-Based Cohort Study: The Lower, the Better

10:30AM-12:30PM: Abstract Number: 2146

Validation of the Simple Calculated Osteoporosis Risk Estimation and Osteoporosis Self-assessment Tool Among People Aging with HIV in Peru

10:30AM-12:30PM: Abstract Number: 2124

WITHDRAWN

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].